Ameliorative potential of pralidoxime in tibial and sural nerve transection-induced neuropathic pain in rats.
The present study was designed to investigate the ameliorative potential of pralidoxime in tibial and sural nerve transection-induced neuropathy in rats. Tibial and sural nerve transection was performed by sectioning tibial and sural nerve portions (2 mm) of the sciatic nerve, and leaving the common peroneal nerve intact. The pinprick, acetone, hot and cold tail immersion tests were performed to assess the degree of motor functions, mechanical hyperalgesia, cold allodynia, heat and cold hyperalgesia respectively. Biochemically, the tissue thio-barbituric acid reactive species (TBARS), super-oxide anion contents (the markers of oxidative stress) and total calcium levels were measured. Tibial sural nerve transection resulted in the development of mechanical hyperalgesia, cold allodynia, heat and cold hyperalgesia along with the rise in oxidative stress and calcium levels. However, administration of pralidoxime (10, 20 mg/kg intraperitoneally (i.p.)) for 14 d attenuated tibial and sural nerve transection-induced cold allodynia, mechanical, hot and cold hyperalgesia. Furthermore, pralidoxime also attenuated tibial and sural nerve transection induced increase in oxidative stress and calcium levels. It may be concluded that pralidoxime has ameliorative potential in attenuating the painful neuropathic state associated with tibial and sural nerve transection, which may possibly be attributed to decrease in oxidative stress and calcium levels.
Kaur
Gurpreet
G
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala-147002, India.
Jaggi
Amteshwar Singh
AS
Singh
Nirmal
N
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D002801:Cholinesterase Reactivators / Q000008:administration & dosage / Q000627:therapeutic use*; D003080:Cold Temperature; D003714:Denervation; D004195:Disease Models, Animal; D005260:Female; D006358:Hot Temperature; D006930:Hyperalgesia / Q000188:drug therapy / Q000473:pathology; D008297:Male; D009437:Neuralgia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018384:Oxidative Stress / Q000187:drug effects; D011220:Pralidoxime Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013481:Superoxides / Q000378:metabolism; D013497:Sural Nerve / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D013979:Tibial Nerve / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology
D002801:Cholinesterase Reactivators; D011220:Pralidoxime Compounds; D017392:Thiobarbituric Acid Reactive Substances; D013481:Superoxides; C028797:pralidoxime; D002118:Calcium